Lexeo Therapeutics Inc stock is traded at $2.91, with a volume of 1,707,396. It is down -10.06% in the last 24 hours and down -11.97% over the past month. Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Previous Close:
$3.23
Open:
$3.23
24h Volume:
1,707,396
Relative Volume:
1.30
Market Cap:
$238.47M
Revenue:
$531.00K
Net Income/Loss:
-$99.96M
P/E Ratio:
-
EPS:
-$2.19
Net Cash Flow:
-$98.96M
1W Performance:
-7.48%
1M Performance:
-11.97%
6M Performance:
-53.37%
1Y Performance:
-65.50%
1-Day Range:
$0.00$0.00
1-Week Range:
$2.78$3.44
52-Week Range:
$2.55$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(212) 547-9879Address
345 PARK AVENUE SOUTH, NEW YORK, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS